Usefulness of Sodium-Glucose Cotransporter 2 Inhibitors for Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus

CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials

Kenneth F. Schulz, Douglas G. Altman, David Moher · BMC Medicine · 2010 · 13.5K citations · Full text

Public Health, Health Policy, Clinical Epidemiology +16

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine · 2015 · 12K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association

Emelia J. Benjamin, Paul Muntner, Álvaro Alonso et al. · Circulation · 2019 · 9.1K citations · Full text

Medicine, Cardiology, Preventive Medicine +11

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey et al. · New England Journal of Medicine · 2017 · 7.8K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Stephen D. Wiviott, Itamar Raz, Marc P. Bonaca et al. · New England Journal of Medicine · 2018 · 6.3K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17